These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 8988726)

  • 1. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
    Häckel C; Czerniak B; Ayala AG; Radig K; Roessner A
    Cancer; 1997 Jan; 79(1):53-8. PubMed ID: 8988726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
    Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
    Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of plasminogen activators and plasminogen activator inhibitors in cutaneous melanomas of transgenic melanoma-susceptible mice.
    de Vries TJ; Kitson JL; Silvers WK; Mintz B
    Cancer Res; 1995 Oct; 55(20):4681-7. PubMed ID: 7553649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF; de Vries C; Hohmann C; Veerman H; Pannekoek H
    J Clin Invest; 1989 Aug; 84(2):647-55. PubMed ID: 2503541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T; Yabe H; Morioka H; Yamada R; Nakagawa T; Toyama Y
    Anticancer Res; 2000; 20(5A):3031-6. PubMed ID: 11062719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C; Bolon I; Gazzeri S; Veyrenc S; Brambilla C; Brambilla E
    Clin Cancer Res; 1999 Aug; 5(8):2094-102. PubMed ID: 10473092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester.
    Gyetko MR; Webb AC; Sitrin RG
    J Immunol; 1988 Oct; 141(8):2693-8. PubMed ID: 3139763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of plasminogen activators and type-1 plasminogen activator inhibitor by cyclic AMP and phorbol ester in rat astrocytes.
    Tranque P; Robbins R; Naftolin F; Andrade-Gordon P
    Glia; 1992; 6(3):163-71. PubMed ID: 1335967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cellular degradation of free and inhibitor-bound tissue-type plasminogen activator--requirement for a co-receptor?
    Camani C; Gavin O; Kruithof EK
    Thromb Haemost; 2000 Feb; 83(2):290-6. PubMed ID: 10739388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of oxidative stress on the expression of t-PA, u-PA, u-PAR, and PAI-1 in endothelial cells.
    Oszajca K; Bieniasz M; Brown G; Swiatkowska M; Bartkowiak J; Szemraj J
    Biochem Cell Biol; 2008 Dec; 86(6):477-86. PubMed ID: 19088796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
    Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
    Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
    J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G; Serra M; Ragazzini P; Magagnoli G; Pazzaglia L; Ponticelli F; Ferrari C; Zanasi M; Bertoni F; Picci P; Benassi MS
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of mRNA levels for urinary- and tissue-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in human fibroblasts by interleukin 1.
    Michel JB; Quertermous T
    J Immunol; 1989 Aug; 143(3):890-5. PubMed ID: 2501387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G; Tavian D; Copeta A; Portolani N; Giulini SM; Barlati S
    Cancer Res; 1998 May; 58(10):2234-9. PubMed ID: 9605771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC; Heiss MM; Simon EH; Gruetzner KU; Babic R; Jauch KW; Schildberg FW; Allgayer H
    Cancer; 2006 Mar; 106(5):1026-35. PubMed ID: 16435385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein and messenger RNA levels of plasminogen activators and inhibitors analyzed in 22 human tumor cell lines.
    Quax PH; van Leeuwen RT; Verspaget HW; Verheijen JH
    Cancer Res; 1990 Mar; 50(5):1488-94. PubMed ID: 2105839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM; Van Geloof WL; Straatman H; Van De Molengraft FJ; Van Muijen GN; Ruiter DJ
    J Pathol; 2002 Sep; 198(1):92-9. PubMed ID: 12210068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative analysis of the proteinase specificity in wild-type and stabilized plasminogen activator inhibitor-1: evidence for contribution of intramolecular flexibility.
    De Taeye B; Gils A; Vleugels N; Rabijns A; Declerck PJ
    Biochem Biophys Res Commun; 2004 Aug; 321(3):746-51. PubMed ID: 15358169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.